General Pharmacology — MCQs

General Pharmacology Indian Medical PG Practice Questions and MCQs

Question 181: Plasma drug monitoring is indicated for which type of drug?

A. Drugs with a high safety margin
B. Drugs with a narrow therapeutic index (Correct Answer)
C. Drugs with a wide therapeutic index
D. None of the above

Explanation: **Explanation:** **Therapeutic Drug Monitoring (TDM)** is the clinical practice of measuring drug concentrations in plasma to maintain them within a specific "therapeutic window." **Why Option B is Correct:** Drugs with a **narrow therapeutic index (NTI)** have a very small margin between the dose required for a therapeutic effect and the dose that causes toxicity. For these drugs, standard dosing can lead to unpredictable plasma levels due to individual pharmacokinetic variations. Monitoring is essential to ensure efficacy while preventing life-threatening toxicity. Examples include Digoxin, Lithium, Phenytoin, and Aminoglycosides. **Why Other Options are Incorrect:** * **Options A & C:** Drugs with a **high or wide therapeutic index** (e.g., Penicillin, Paracetamol) are inherently safer. The dose required to produce toxicity is significantly higher than the effective dose. Therefore, routine plasma monitoring is unnecessary and not cost-effective, as clinical observation usually suffices. **NEET-PG High-Yield Pearls:** * **Indications for TDM:** Narrow therapeutic index, drugs with high first-pass metabolism, non-compliance suspected, or when toxicity is difficult to distinguish from the disease itself (e.g., Digoxin-induced arrhythmias). * **TDM is NOT useful for:** "Hit and run" drugs (e.g., Reserpine, MAO inhibitors), drugs with easily measurable physiological markers (e.g., BP for antihypertensives, INR for Warfarin, Blood sugar for Insulin), and irreversible inhibitors. * **Mnemonic for NTI Drugs:** **W**arfarin, **T**heophylline, **D**igoxin, **L**ithium, **P**henytoin (**W**hen **T**he **D**rugs **L**evels **P**eak).

Question 182: Which of the following is true regarding drugs administered intravenously?

A. They are rapidly absorbed.
B. They are subject to first-pass metabolism.
C. They have 100% bioavailability. (Correct Answer)
D. All of the above.

Explanation: ### Explanation **1. Why Option C is Correct:** Bioavailability is defined as the fraction of an administered dose of unchanged drug that reaches the systemic circulation. When a drug is administered **intravenously (IV)**, it is injected directly into the bloodstream, bypassing all barriers to absorption (like the gut wall) and avoiding initial metabolism by the liver. Therefore, the entire dose reaches the systemic circulation, resulting in **100% bioavailability ($F = 1.0$)**. This makes the IV route the gold standard for comparing the bioavailability of other routes. **2. Why Other Options are Incorrect:** * **Option A:** "Absorption" refers to the movement of a drug from its site of administration into the central compartment. Since IV drugs are placed directly into the blood, they **bypass the process of absorption** entirely. Absorption is a prerequisite for oral, subcutaneous, or intramuscular routes, but not for IV. * **Option B:** First-pass metabolism occurs when a drug is metabolized (usually in the liver or gut wall) before it reaches systemic circulation. IV drugs enter the systemic veins directly and reach the heart/lungs before being distributed to the liver via the hepatic artery. Thus, they **escape first-pass metabolism**. **3. NEET-PG High-Yield Pearls:** * **Bioavailability ($F$):** Calculated as $\frac{\text{AUC (oral)}}{\text{AUC (IV)}} \times 100$. * **Emergency Use:** The IV route is the route of choice in emergencies due to its **instantaneous onset of action**. * **Loading Dose:** Drugs with large volumes of distribution ($V_d$) often require an IV loading dose to achieve rapid therapeutic plasma concentrations. * **Caution:** IV administration carries the highest risk of toxicity and "speed shock" if injected too rapidly; it is also the most difficult route to reverse once the drug is given.

Question 183: At 12 hours after intravenous administration of a bolus dose, the plasma level of a drug is 3 mg/L. If the volume of distribution (Vd) is 10 L and the elimination half-life is 6 hours, what was the dose administered?

A. 120 mg (Correct Answer)
B. 180 mg
C. 240 mg
D. 480 mg

Explanation: ### Explanation To solve this problem, we must work backward from the current plasma concentration to the initial concentration ($C_0$) using the concept of **half-life ($t_{1/2}$)** and then calculate the dose using the **Volume of Distribution ($V_d$)**. **Step 1: Calculate the number of half-lives elapsed.** * Time elapsed = 12 hours; Half-life ($t_{1/2}$) = 6 hours. * Number of half-lives ($n$) = $12 / 6 = 2$ half-lives. **Step 2: Determine the initial plasma concentration ($C_0$).** * After 1 half-life, the concentration is $1/2$ of $C_0$. * After 2 half-lives, the concentration is $1/4$ of $C_0$. * Given: Concentration at 12 hours ($C_{12}$) = 3 mg/L. * Therefore, $C_0 = 3 \text{ mg/L} \times 2 \times 2 = \mathbf{12 \text{ mg/L}}$. **Step 3: Calculate the Dose.** * Formula: $\text{Dose} = V_d \times C_0$ * $\text{Dose} = 10 \text{ L} \times 12 \text{ mg/L} = \mathbf{120 \text{ mg}}$. --- ### Analysis of Options * **A (120 mg): Correct.** This accounts for two half-lives of decay (from 12 mg/L to 3 mg/L) across a 10 L volume. * **B (180 mg): Incorrect.** This value would result if one assumed 1.5 half-lives or made a calculation error in the $V_d$ multiplication. * **C (240 mg): Incorrect.** This would be the dose if the concentration was 3 mg/L after 3 half-lives (18 hours). * **D (480 mg): Incorrect.** This would be the dose if the concentration was 3 mg/L after 4 half-lives (24 hours). --- ### Clinical Pearls for NEET-PG 1. **First-Order Kinetics:** Most drugs follow first-order kinetics, where a constant *fraction* of the drug is eliminated per unit time. 2. **Steady State:** It takes approximately **4–5 half-lives** to reach steady-state concentration during constant infusion. 3. **Vd Significance:** A high $V_d$ (>40L) suggests the drug is sequestered in tissues (lipophilic), while a low $V_d$ suggests the drug remains in the plasma (highly protein-bound or large molecules). 4. **Loading Dose Formula:** $\text{LD} = V_d \times \text{Target Plasma Concentration}$.

Question 184: Which of the following is NOT a type of oxidative drug metabolism?

A. Deamination
B. N-oxidation
C. N-dealkylation
D. Glucuronidation (Correct Answer)

Explanation: ### Explanation Drug metabolism (biotransformation) is divided into two main phases: **Phase I (Non-synthetic)** and **Phase II (Synthetic)**. **Why Glucuronidation is the Correct Answer:** Glucuronidation is a **Phase II reaction**. It involves the conjugation of a drug with glucuronic acid (derived from glucose) via the enzyme **UDP-glucuronosyltransferase (UGT)**. Unlike Phase I reactions, which introduce or expose functional groups, Phase II reactions attach large, polar endogenous molecules to the drug to make it water-soluble for excretion. **Why the other options are incorrect:** Options A, B, and C are all subtypes of **Phase I Oxidative reactions**, primarily mediated by the **Cytochrome P450 (CYP450)** enzyme system: * **Deamination (A):** Removal of an amino group (e.g., metabolism of Amphetamine). * **N-oxidation (B):** Addition of oxygen to a nitrogen atom (e.g., metabolism of Trimethylamine). * **N-dealkylation (C):** Removal of an alkyl group attached to a nitrogen atom (e.g., Morphine to Normorphine). **High-Yield Clinical Pearls for NEET-PG:** * **Phase I Reactions:** Oxidation (most common), Reduction, and Hydrolysis. * **Phase II Reactions:** Glucuronidation (most common Phase II), Acetylation, Methylation, and Sulfate conjugation. * **Microsomal vs. Non-microsomal:** Glucuronidation is the **only** Phase II reaction carried out by microsomal enzymes (located in the smooth ER). All other Phase II reactions are non-microsomal (cytosolic). * **Gray Baby Syndrome:** Occurs in neonates due to a deficiency of the UGT enzyme, leading to the inability to conjugate Chloramphenicol.

Question 185: Which of the following receptors has an intrinsic ion channel?

A. Histamine H1 receptor
B. Histamine H2 receptor
C. Adrenergic alpha receptor
D. GABA-benzodiazepine receptor (Correct Answer)

Explanation: ### Explanation **1. Why the Correct Answer is Right:** The **GABA-A receptor** (part of the GABA-benzodiazepine receptor complex) is a classic example of a **Ligand-Gated Ion Channel (Ionotropic Receptor)**. It is a pentameric structure that, upon activation by GABA, opens an intrinsic **Chloride (Cl⁻) channel**. The resulting influx of chloride ions causes hyperpolarization of the post-synaptic neuron, leading to CNS inhibition. Benzodiazepines act as positive allosteric modulators, increasing the *frequency* of channel opening. **2. Why the Other Options are Incorrect:** * **Histamine H1 & H2 Receptors:** Both are **G-Protein Coupled Receptors (GPCRs)**. H1 is coupled to the **Gq** protein (activating the PLC-IP3/DAG pathway), while H2 is coupled to the **Gs** protein (increasing cAMP). * **Adrenergic Alpha Receptors:** All adrenergic receptors (Alpha and Beta) are **GPCRs**. Alpha-1 is Gq-linked, while Alpha-2 is Gi-linked (inhibitory). They do not contain intrinsic ion channels. **3. High-Yield Clinical Pearls for NEET-PG:** * **Ionotropic Receptors (Fastest):** Include Nicotinic ACh (Na⁺/K⁺), GABA-A (Cl⁻), Glycine (Cl⁻), and 5-HT3 (Na⁺/K⁺). Note: 5-HT3 is the *only* serotonin receptor that is ionotropic. * **Metabotropic Receptors (GPCRs):** These are the most common targets for drugs. They act via second messengers (cAMP, IP3, DAG). * **GABA-B:** Unlike GABA-A, the GABA-B receptor is a **GPCR** (linked to Gi) that works by opening K⁺ channels or closing Ca²⁺ channels. * **Benzodiazepines vs. Barbiturates:** Benzodiazepines increase the **frequency** of Cl⁻ channel opening; Barbiturates increase the **duration** of opening.

Question 186: What type of antagonism does protamine exhibit towards heparin?

A. Competitive
B. Chemical (Correct Answer)
C. Toxic
D. Noncompetitive

Explanation: ### Explanation **Correct Answer: B. Chemical Antagonism** **Why it is correct:** Chemical antagonism occurs when two substances react chemically in solution to form an inactive product, thereby neutralizing the effect of one another without involving a specific receptor site. * **Heparin** is a highly acidic, negatively charged molecule (due to sulfate groups). * **Protamine sulfate** is a highly basic, positively charged protein (rich in arginine). When administered, protamine binds ionically to heparin to form a stable, inactive **salt complex**. This direct chemical neutralization makes it the classic example of chemical antagonism. **Why the other options are incorrect:** * **A & D (Competitive and Noncompetitive):** These are types of **pharmacologic antagonism** where the antagonist competes for or binds to the same receptor as the agonist. Heparin does not act through a traditional receptor; it acts by activating Antithrombin III in the plasma. * **C (Toxic):** This is not a standard classification of antagonism. While protamine can have toxic effects (like hypotension or anaphylaxis) if given too rapidly, the term describes a side effect profile rather than the mechanism of interaction. **NEET-PG High-Yield Pearls:** * **Antidote Ratio:** 1 mg of Protamine neutralizes approximately 100 units of Heparin. * **Source:** Protamine is derived from the sperm of salmon or other fish. * **Clinical Caution:** Rapid injection of protamine can cause histamine release, leading to systemic hypotension and pulmonary hypertension. * **Other Examples of Chemical Antagonism:** * Chelating agents (e.g., Dimercaprol) binding to heavy metals. * Antacids neutralizing gastric HCl.

Question 187: Fenfluramine is used in which of the following conditions?

A. Obesity (Correct Answer)
B. Malignancy
C. Hypertension
D. None of the above

Explanation: **Fenfluramine** is a sympathomimetic amine that acts primarily as a **serotonin-releasing agent**. It increases the level of extracellular serotonin in the hypothalamus, which stimulates the satiety center and suppresses appetite (anorexiant effect). Historically, it was widely used for the management of **Obesity** (Option A) [1], often in combination with phentermine (the "Fen-Phen" regimen).Why other options are incorrect:* **Malignancy (Option B):** Fenfluramine has no cytotoxic or anti-neoplastic properties. In fact, weight loss is a common complication of malignancy (cachexia), where appetite stimulants (like Megestrol) would be indicated instead.* **Hypertension (Option C):** Fenfluramine is contraindicated in hypertension. As a sympathomimetic, it can increase blood pressure. Furthermore, its use is strongly associated with **Pulmonary Arterial Hypertension (PAH)** [2].**High-Yield NEET-PG Pearls:**1. **Withdrawal:** Fenfluramine was withdrawn from the global market in 1997 due to serious adverse effects, specifically **cardiac valvular fibrosis** and **Pulmonary Hypertension** [2].2. **Mechanism of Toxicity:** The valvular damage is mediated by the activation of **5-HT2B receptors** on cardiac valvular interstitial cells.3. **Recent Update:** In 2020, low-dose Fenfluramine was FDA-approved for a new indication: the treatment of seizures associated with **Dravet Syndrome** and **Lennox-Gastaut Syndrome** (pediatric epileptic encephalopathies).4. **Isomer:** **Dexfenfluramine** is the d-isomer of fenfluramine, which was also used for obesity before being withdrawn for similar cardiac risks [2].

Question 188: What is the significance of pKa in relation to a drug's ionization?

A. The pH at which 50% of the drug is in its active form.
B. The pH at which 50% of the drug is ionized and 50% is non-ionized. (Correct Answer)
C. The pH at which all of the drug is in its non-ionized form.
D. The pH at which all of the drug is in its ionized form.

Explanation: **Explanation:** The concept of **pKa** is derived from the **Henderson-Hasselbalch equation**. By definition, pKa is the negative logarithm of the acid dissociation constant ($Ka$). It represents the specific pH at which a drug exists in a state of equilibrium, where exactly **50% of the molecules are ionized (charged) and 50% are non-ionized (uncharged).** **Why Option B is Correct:** When the ambient pH equals the pKa of a drug, the ratio of ionized to non-ionized forms becomes 1:1. This is a critical pharmacokinetic threshold because only the **non-ionized** form is lipid-soluble and can cross biological membranes (like the blood-brain barrier or GI mucosa). **Analysis of Incorrect Options:** * **Option A:** "Active form" is misleading. While the non-ionized form is better absorbed, the ionized form is often the one that binds to receptors or remains trapped in compartments. * **Options C & D:** Drugs exist in varying proportions of ionization across the pH scale. Total ionization or non-ionization only occurs at pH levels several units away from the pKa, not at the pKa itself. **NEET-PG High-Yield Pearls:** 1. **Ion Trapping:** This principle is used in toxicology. To treat **Aspirin (acidic drug) poisoning**, we alkalinize the urine with Sodium Bicarbonate. This increases the ionized fraction of the drug in the renal tubules, preventing reabsorption and enhancing excretion. 2. **Acidic Drugs (e.g., NSAIDs, Phenytoin):** Are better absorbed in acidic environments (Stomach) because they remain non-ionized. 3. **Basic Drugs (e.g., Morphine, Amphetamines):** Are better absorbed in alkaline environments (Small Intestine).

Question 189: What is the mechanism of action of sildenafil?

A. Inhibition of adenosine deaminase
B. Inhibition of phosphodiesterase-5 (Correct Answer)
C. Inhibition of Aminopeptidase
D. Inhibition of Guanylyl cyclase

Explanation: **Explanation:** **Mechanism of Action:** Sildenafil is a selective inhibitor of **Phosphodiesterase-5 (PDE-5)**. In the corpus cavernosum, sexual stimulation leads to the release of Nitric Oxide (NO), which activates the enzyme guanylyl cyclase [1, 5]. This increases levels of **cyclic Guanosine Monophosphate (cGMP)**, causing smooth muscle relaxation and increased blood flow (erection) [3, 5]. PDE-5 is the enzyme responsible for the degradation of cGMP. By inhibiting PDE-5, sildenafil prevents the breakdown of cGMP, thereby enhancing and prolonging the vasodilatory effect of NO [1, 3]. **Analysis of Incorrect Options:** * **Option A (Adenosine deaminase):** Inhibited by drugs like **Pentostatin**, used in hairy cell leukemia. * **Option C (Aminopeptidase):** Inhibited by **Bestatin** (Ubenimex), an immunomodulator. * **Option D (Guanylyl cyclase):** Sildenafil actually *potentiates* the downstream effects of this enzyme; it does not inhibit it. Drugs like nitrates stimulate guanylyl cyclase [3]. **NEET-PG High-Yield Pearls:** * **Clinical Uses:** Erectile dysfunction and **Pulmonary Arterial Hypertension (PAH)** [1, 3]. * **Contraindication:** Must never be co-administered with **Nitrates** (e.g., Nitroglycerin) as it can cause life-threatening hypotension due to synergistic increases in cGMP [3]. * **Side Effects:** Headache, flushing, and **Cyanopsia** (blue-tinted vision) due to weak cross-inhibition of PDE-6 in the retina. * **Tadalafil vs. Sildenafil:** Tadalafil has a much longer half-life (approx. 18 hours) compared to sildenafil (approx. 4 hours).

Question 190: Sildenafil acts by which mechanism?

A. Increasing cGMP (Correct Answer)
B. Decreasing cGMP
C. Increasing cAMP
D. Decreasing cAMP

Explanation: ### Explanation **Mechanism of Action (Why A is correct):** Sildenafil is a selective inhibitor of the enzyme **Phosphodiesterase-5 (PDE-5)**. In the corpus cavernosum of the penis and the pulmonary vasculature, Nitric Oxide (NO) stimulates the enzyme guanylyl cyclase, which converts GTP into **cyclic Guanosine Monophosphate (cGMP)**. cGMP causes smooth muscle relaxation and vasodilation. Normally, PDE-5 breaks down cGMP to terminate this signal. By inhibiting PDE-5, Sildenafil prevents the degradation of cGMP, leading to its **increased levels**, prolonged vasodilation, and improved erectile function. **Analysis of Incorrect Options:** * **B (Decreasing cGMP):** This would cause vasoconstriction and smooth muscle contraction, the opposite of Sildenafil’s intended effect. * **C & D (cAMP pathways):** While drugs like Milrinone (PDE-3 inhibitor) or Alprostadil (PGE1 analog) work via the **cyclic Adenosine Monophosphate (cAMP)** pathway, Sildenafil is highly selective for PDE-5, which specifically degrades cGMP, not cAMP. **NEET-PG High-Yield Pearls:** * **Clinical Uses:** Erectile dysfunction and Pulmonary Arterial Hypertension (PAH). * **Absolute Contraindication:** Never co-administer with **Nitrates** (e.g., Nitroglycerin). Both increase cGMP through different mechanisms, leading to synergistic vasodilation and potentially fatal hypotension. * **Side Effects:** Headache, flushing, and **Cyanopsia** (blue-tinted vision) due to weak inhibition of PDE-6 in the retina. * **Metabolism:** Primarily by **CYP3A4**; inhibitors like Erythromycin or Ketoconazole can increase its toxicity.

Practice by Chapter

Pharmacokinetics: Absorption and Distribution

Practice Questions

Pharmacokinetics: Metabolism and Excretion

Practice Questions

Pharmacodynamics and Receptor Theory

Practice Questions

Drug-Receptor Interactions and Dose-Response

Practice Questions

Pharmacogenetics and Personalized Medicine

Practice Questions

Adverse Drug Reactions and Toxicity

Practice Questions

Drug Interactions

Practice Questions

Drug Development and Regulation

Practice Questions

Pediatric and Geriatric Pharmacology

Practice Questions

Placental Transfer and Lactation

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free